CLOs on the Move

Athenex

www.athenex.com

 
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.athenex.com
  • 1001 Main Street Suite 600
    Buffalo, NY USA 14203
  • Phone: 716.427.2950

Executives

Name Title Contact Details
Teresa Bair
 General Counsel and Senior Vice President of Administration Profile
Teresa Bair
 Executive Officer, General Counsel and Senior Vice President of Administration Profile

Similar Companies

Cardiology Associates

Cardiology Associates of Alabama offers vascular care and heart treatments including structural heart, interventional procedures, pediatric cardiology, heart rhythm disorders, and congestive heart failure.

Advantage Surgical & Wound Care

Advantage Surgical And Wound Care heals wounds and treats surgical conditions in the post-acute environment through conservative, evidence-based care.

itsRX

itsRX is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Blue Earth Diagnostics

Blue Earth Diagnostics (BED) is a privately held diagnostics company focused on the development and commercialisation of molecular imaging technologies.

Eledon

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.